IntraLase Receives Approval in Taiwan for Sales of Its FS Laser System; Company Plans Immediate Commercialization to Further Ex

IntraLase Corp. (NASDAQ:ILSE), manufacturer of the
ultra-fast laser that is revolutionizing refractive and corneal
surgery, today announced that Taiwan has granted approval for the sale
of the company's femtosecond laser in that nation.
   The company plans to immediately commercialize the IntraLase(R) FS
laser in Taiwan, further expanding its global presence. As of June 30,
2006, 471 IntraLase lasers were installed around the world and over
850,000 IntraLase LASIK procedures had been performed in ophthalmic
practices worldwide.
   Taiwan Hwa-In, IntraLase's distributor in Hong Kong and Mainland
China, will begin offering the company's products in Taiwan
immediately. Mr. Jay Hsu, Chief Executive Officer of Taiwan Hwa-In,
stated, "The added safety of the IntraLase Method(TM) in LASIK will
provide excellent momentum to drive patient demand in Taiwan, which
has a very large number of patients seeking safer and more reliable
treatments." Mr. Hsu continued, "Taiwan Hwa-In is a leader in the
Taiwanese refractive market, with over 20 years experience, and this
approval allows us to help doctors in Taiwan provide bladeless LASIK
surgery to their patients."
   "The Taiwanese market represents an exciting opportunity and
further demonstrates the global potential of IntraLase technology,"
said Robert J. Palmisano, President and Chief Executive Officer of
IntraLase Corp. "We look forward to entering this market and helping
Taiwanese practitioners offer clinically-proven safety and improved
visual outcomes to their patients."

   About IntraLase Corp.

   IntraLase designs, develops, and manufactures an ultra-fast laser
that is revolutionizing refractive and corneal surgery by creating
safe and more precise corneal incisions. Delivering on the promise of
ophthalmic laser technology, the IntraLase FS laser, related software,
and disposable devices replace the hand-held microkeratome blade used
during LASIK surgery. The unsurpassed accuracy of IntraLase's
computer-controlled femtosecond laser has been shown to improve safety
profiles and visual outcomes when used during LASIK. Additionally, the
IntraLase FS laser creates precision-designed intracorneal incisions
that when combined can be used during lamellar and penetrating
keratoplasty, and intrastromal ring implantation. IntraLase is
presently in the process of commercializing applications of its
technology in the treatment of corneal diseases that require corneal
transplant surgery. The company's proprietary laser and disposable
patient interfaces are presently marketed throughout the United States
and 31 other countries. IntraLase is headquartered and manufactures
its products in Irvine, California. For additional information, visit
the company's web site: www.intralase.com.

   Forward Looking Statements

   Statements contained in this press release that are not historical
information are forward-looking statements as defined within the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "anticipate," "intend," "plan," "estimate," "project," or
words of similar meaning, or future or conditional verbs such as
"will," "would," "should," "could," or "may." Such forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially from those projected or implied.
Those risks and uncertainties include, but are not limited to: the
degree of continued acceptance of LASIK surgery; potential
complications revealed by long-term follow up; the extent of adoption
of our product offering by LASIK surgeons; general economic
conditions; changes in federal tax laws governing the ability of
potential LASIK patients to use pre-tax dollars to pay for LASIK
surgery; the scope of government regulation applicable to our
products; patients' willingness to pay for LASIK surgery; our ability
to compete against our competitors; the effectiveness of our measures
to ensure full payment of procedure fees; the occurrence and outcome
of product liability suits against us; our ability to adequately
protect our intellectual property; whether we become subject to claims
of infringement or misappropriation of the intellectual property
rights of others; the continued availability of supplies from
single-source suppliers and manufacturers of our key laser components;
the ability of our managers, operations, and facilities to manage our
growth; the success of our expansion into markets outside the United
States; whether we lose any of our key executives or fail to attract
qualified personnel; or if our new products or applications fail to
become commercially viable.
   Certain of these risks and uncertainties, in addition to other
risks, are more fully described in the company's quarterly report on
Form 10-Q for the period ending June 30, 2006, as filed with the
Securities and Exchange Commission on August 1, 2006.
   These forward-looking statements are made only as of the date of
this press release, and the company assumes no obligation to update or
revise the forward-looking statements, whether as a result of new
information, future events, or otherwise.